Table 3 FDA-approved immune checkpoint inhibitors with approved indications
No | Drug Name | Generic Name | Target | Date of Approval | Applications |
|---|---|---|---|---|---|
1 | Ipilimumab | Yervoy® | CTLA-4 | 2011 | 1. Melanoma 2. Renal cell carcinoma 3. CRC 4. HCC 5. NSCC 6. Malignant pleural mesothelioma 7. Esophageal cancer |
2 | Tremelimumab | Imjudo® | CTLA-4 | 2022 | 1. HCC 2. Mesothelioma |
3 | Pembrolizumab | Keytruda® | PD-1 | 2014 | 1. NSCC 2. HCC 3. CSCC 4. RCC 5. HNSCC 6. Urothelial carcinoma 7. NMIBC 8. Colorectal cancer 9. gastric cancer 10. Esophageal cancer 11. Cervical cancer 12. Merkel cell carcinoma 13. Endometrial carcinoma 14. Classical Hodgkin lymphoma 15. Primary mediastinal large B-cell lymphoma 16. Triple-negative breast cancer |
4 | Nivolumab | Opdivo® | PD-1 | 2014 | 1. NSCC 2. Melanoma 3. RCC 4. malignant pleural mesothelioma 5. Classical Hodgkin lymphoma 6. SCC 7. Urothelial carcinoma 8. Colorectal cancer 9. HCC 10 Esophageal cancer 11. Gastric cancer 12. Gastroesophageal junction cancer 13. Esophageal adenocarcinoma |
5 | Cemiplimab | Libtayo® | PD-1 | 2019 | 1. SCC 2. BCC 3. NSCC |
6 | Dostarlimab | Jemperli® | PD-1 | 2021 | Endometrial cancer |
7 | Durvalumab | Imfinzi® | PD-L1 | 2017 | 1. NSCC 2. SCLC 3. HCC 4. Biliary tract cancer |
8 | Atezolizumab | Tecentriq® | PD-L1 | 2016 | 1. HCC 2. NSCC 3. SCLC 4. ASPS 5. Melanoma |
9 | Avelumab | Bavencio® | PD-L1 | 2017 | 1. Urothelial carcinoma 2. MCC 3. RCC |
10 | Relatlimab | Opdualag® | LAG-3 | 2022 | Melanoma |